References
Bardowell, S. A., Parker, J., Fan, C., Crandell, J., Perou, C. M., & Swift-Scanlan, T. (2013). Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Research and Treatment, 142, 365-380. doi:10.1007/s10549-013-2738-0
Bertucci, F., Finetti, P., & Birnbaum, D. (2012). Basal breast cancer: A complex and deadly molecular subtype. Current Molecular Medicine, 12, 96-110. doi:10.2174/156652412798376134
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008). How basal are triple-negative breast cancers? International Journal of Cancer, 123, 236-240. doi:10.1002/ijc.23518
Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000). The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA czross-linking agent cisplatin. Journal of Biological Chemistry, 275, 23899-23903. doi:10.1074/jbc.C000276200
Binkley, J. M., Harris, S. R., Levangie, P. K., Pearl, M., Guglielmino, J., Kraus, V., & Rowden, D. (2012). Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer, 118(Suppl.), 2207-2216. doi:10.1002/cncr.27469
Cancer Genome Atlas Network. (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61-70. doi:10.1038/nature11412
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., … Perou, C. M. (2007). The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research, 13, 2329-2334. doi:10.1158/1078-0432.CCR-06-1109
Cheang, M. C., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., … Nielsen, T. O. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research, 14, 1368-1376. doi:10.1158/1078-0432.CCR-07-1658
Chia, S. K., Bramwell, V. H., Tu, D., Shepherd, L. E., Jiang, S., Vickery, T., … Nielsen, T. O. (2012). A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clinical Cancer Research, 18, 4465-4472. doi:10.1158/1078-0432.CCR-12-0286
Coyne, E., Wollin, J., & Creedy, D. K. (2012). Exploration of the family's role and strengths after a young woman is diagnosed with breast cancer: Views of women and their families. European Journal of Oncology Nursing, 16, 124-130. doi:10.1016/j.ejon.2011.04.013
Creighton, C. J. (2012). The molecular profile of luminal B breast cancer. Biologics: Targets and Therapy, 6, 289-297. doi:10.2147/BTT.S29923
D'Anello, L., Sansone, P., Storci, G., Mitrugno, V., D'Uva, G., Chieco, P., & Bonafé, M. (2010). Epigenetic control of the basal-like gene expression profile via interleukin-6 in breast cancer cells. Molecular Cancer, 9, 300. doi:10.1186/1476-4598-9-300
DeSantis, C., Ma, J., Bryan, L., & Jemal, A. (2013). Breast cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 64, 52-62. doi:10.3322/caac.21203
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., … Frost, D. J. (2007). ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical Cancer Research, 13, 2728-2737. doi:10.1158/1078-0432.CCR-06-3039
Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews. Cancer, 9, 550-562. doi:10.1038/nrc2664
Eroles, P., Bosch, A., Pérez-Fidalgo, J. A., & Lluch, A. (2012). Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews, 38, 698-707.
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., … Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-921. doi:10.1038/nature03445
Feinberg, A. P. (2008). Epigenetics at the epicenter of modern medicine. JAMA, 299, 1345-1350. doi:10.1001/jama.299.11.1345
Florea, A. M., & Büsselberg, D. (2011). Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers, 3(1), 1351-1371. doi:10.3390/cancers3011351
Goncalves, R., & Bose, R. (2013). Using multigene tests to select treatment for early-stage breast cancer. Journal of the National Comprehensive Cancer Network, 11, 174-182.
Gown, A. M. (2008). Current Issues in ER and HER2 testing by IHC in breast cancer. Modern Pathology, 21(Suppl. 2), S8-S15. doi:10.1038/modpathol.2008.34
Gronwald, J., Byrski, T., Huzarski, T., Dent, R., Bielicka, V., Zuziak, R., … Narod, S. (2009). Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Journal of Clinical Oncology, 27(15, Suppl.), 502. doi:10.1186/1897-4287-9-S2-A4
Grushko, T. A., Nwachukwu, C., Charoenthammaraksa, S., Huo, D., Khramtsov, A., Mashek, C., … Olopade, O. I. (2010). Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. Journal of Clinical Oncology, 28(15S), 10510.
Hinshelwood, R. A., & Clark, S. J. (2008). Breast cancer epigenetics: Normal human mammary epithelial cells as a model system. Journal of Molecular Medicine, 86, 1315-1328. doi:10.1007/s00109-008-0386-3
Hoadley, K. A., Weigman, V. J., Fan, C., Sawyer, L. R., He, X., Troester, M. A., … Perou, C. M. (2007). EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics, 8, 258. doi:10.1186/1471-2164-8-258
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., … Lackner, M. R. (2009). In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clinical Cancer Research, 15, 4649-4664. doi:10.1158/1078-0432.CCR-09-0317
Holm, K., Hegardt, C., Staaf, J., Vallon-Christersson, J., Jönsson, G., Olsson, H., … Ringnér, M. (2010). Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Research, 12(3), R36. doi:10.1186/bcr2590
Jiang, Z., Jones, R., Liu, J. C., Deng, T., Robinson, T., Chung, P. E., … Zacksenhaus, E. (2011). RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle, 10, 1563-1570. doi:10.4161/cc.10.10.15703
Kashiwagi, S., Yashiro, M., Takashima, T., Aomatsu, N., Kawajiri, H., Ogawa, Y., … Hirakawa, K. (2013). C-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. British Journal of Surgery, 100, 490-496. doi:10.1002/bjs.9021
Lee, J. S., Fackler, M. J., Lee, J. H., Choi, C., Park, M. H., … Sukumar, S. (2010). Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biology and Therapy, 9, 1017-1024. doi:10.4161/cbt.9.12.11804
Leung, M., Rosen, D., Fields, S., Cesano, A., & Budman, D. R. (2011). Poly(ADP-ribose) polymerase-1 inhibition: Preclinical and clinical development of synthetic lethality. Molecular Medicine, 17, 854-862.
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, A., … Pusztai, L. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology, 26, 1275-1281. doi:10.1200/JCO.2007.14.4147
Litsas, G. (2013). Individualizing care for women with early-stage breast cancer: The role of molecular assays. Clinical Journal of Oncology Nursing, 17, 332-334. doi:10.1188/13.CJON.332-334
López-Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K., Qiu, M. R., Crea, P., … Sutherland, R. L. (2009). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. International Journal of Cancer, 126, 1121-1131. doi:10.1002/ijc.24831
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B., Brawley, O. W., … Eley, J. W. (2009). Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Research and Treatment, 113, 357-370. doi:10.1007/s10549-008-9926-3
Millikan, R. C., Newman, B., Tse, C. K., Moorman, P. G., Conway, K., Dressler, L. G., … Perou, C. M. (2008). Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment, 109, 123-139. doi:10.1007/s10549-007-9790-6
Moestue, S. A., Dam, C. G., Gorad, S. S., Kristian, A., Bofin, A., Mælandsmo, G. M., … Bjørkøy, G. (2013). Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Research, 15(1), R16. doi:10.1186/bcr3391
Newton, D. A., Rao, K. M., Dluhy, R. A., & Baatz, J. E. (2006). Hemoglobin is expressed by alveolar epithelial cells. Journal of Biological Chemistry, 281, 5668-5676. doi:10.1074/jbc.M509314200
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., … Perou, C. M. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research, 10, 5367-5374. doi:10.1158/1078-0432.CCR-04-0220
O'Brien, K. M., Cole, S. R., Tse, C. K., Perou, C. M., Carey, L. A., Foulkes, W. D., … Millikan, R. C. (2010). Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clinical Cancer Research, 16, 6100-6110. doi:10.1158/1078-0432.CCR-10-1533
Oliveras-Ferraros, C., Vazquez-Martin, A., López-Bonet, E., Martín-Castillo, B., Del Barco, S., Brunet, J., & Menendez, J. A. (2008). Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. International Journal of Oncology, 33, 1165-1176. doi:10.3892/ijo_00000106
Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., … Bernard, P. S. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology, 27, 1160-1167. doi:10.1200/JCO.2008.18.1370
Pedersen, A. E., Hack, T. F., McClement, S. E., & Taylor-Brown, J. (2014). An exploration of the patient navigator role: Perspectives of younger women with breast cancer. Oncology Nursing Forum, 41, 77-88. doi:10.1188/14.ONF.77-88
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., … Botstein, D. (2000). Molecular portraits of human breast tumours. Nature, 406, 747-752. doi:10.1038/35021093
Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., & Harkin, D. P. (2003). BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Research, 63, 6221-6228.
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008). Basal-like breast cancer: A critical review. Journal of Clinical Oncology, 26, 2568-2581. doi:10.1200/JCO.2007.13.1748
Rodríguez-Paredes, M., & Esteller, M. (2011). Cancer epigenetics reaches mainstream oncology. Nature Medicine, 17, 330-339. doi:10.1038/nm.2305
Rody, A., Karn, T., Solbach, C., Gaetje, R., Munnes, M., Kissler, S., … Kaufmann, M. (2007). The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast, 16, 235-240. doi:10.1016/j.breast.2007.02.006
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., … Pusztai, L. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research, 11, 5678-5685. doi:10.1158/1078-0432.CCR-04-2421
Schmid-Büchi, S., Halfens, R. J., Müller, M., Dassen, T., & van den Borne, B. (2013). Factors associated with supportive care needs of patients under treatment for breast cancer. European Journal of Oncology Nursing, 17, 22-29. doi:10.1016/j.ejon.2012.02.003
Shapiro, C. L., & Recht, A. (2001). Side effects of adjuvant treatment of breast cancer. New England Journal of Medicine, 344, 1997-2008. doi:10.1056/NEJM200106283442607
Siziopikou, K. P., & Cobleigh, M. (2007). The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast, 16, 104-107. doi:10.1016/j.breast.2006.09.003
Sorlie, T. (2004). Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. European Journal of Cancer, 40, 2667-2675. doi:10.1016/j.ejca.2004.08.021
Spittler, C. A., Pallikathayil, L., & Bott, M. (2012). Exploration of how women make treatment decisions after a breast cancer diagnosis [Online exclusive]. Oncology Nursing Forum, 39, E425-E433. doi:10.1188/12.ONF.E425-E433
Toft, D. J., & Cryns, V. L. (2011). Minireview: Basal-like breast cancer: From molecular profiles to targeted therapies. Molecular Endocrinology, 25, 199-211. doi:10.1210/me.2010-0164
Tomaskovic-Crook, E., Thompson, E. W., & Thiery, J. P. (2009). Epithelial to mesenchymal transition and breast cancer. Breast Cancer Research, 11, 213. doi:10.1186/bcr2416
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., … Tutt, A. N. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 26, 2126-2132. doi:10.1038/sj.onc.1210014
Ulirsch, J., Fan, C., Knafl, G., Wu, M. J., Coleman, B., Perou, C. M., & Swift-Scanlan, T. (2013). Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Research and Treatment, 137, 383-396. doi:10.1007/s10549-012-2353-5
Waddington, C. H. (2012). The epigenotype. 1942. International Journal of Epidemiology, 41, 10-13.
Widakowich, C., de Castro, G., Jr., De Azambuja, E., Dinh, P., & Awada, A. (2007). Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist, 12, 1443-1455. doi:10.1634/theoncologist.12-12-1443
Wong, K. K., Engelman, J. A., & Cantley, L. C. (2010). Targeting the PI3K signaling pathway in cancer. Current Opinion in Genetics and Development, 20, 87-90. doi:10.1016/j.gde.2009.11.002
Yang, X. R., Sherman, M. E., Rimm, D. L., Lissowska, J., Brinton, L. A., Peplonska, B., … García-Closas, M.(2007). Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiology Biomarkers and Prevention, 16, 439-443. doi:10.1158/1055-9965.EPI-06-0806
Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology, 2, 127-137. doi:10.1038/35052073
Yehiely, F., Moyano, J. V., Evans, J. R., Nielsen, T. O., & Cryns, V. L. (2006). Deconstructing the molecular portrait of basal-like breast cancer. Trends in Molecular Medicine, 12, 537-544.